News

Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen
Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...
Eli Lilly's Alzheimer's Drug Gets Approval in Australia
Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing ...
Former Eli Lilly CEOs donate $20 million to fund new institute at IU Health
The Tobias-Lechleiter Institute for Clinical Innovation will serve as a hub for "groundbreaking" disease detection and ...
Fierce Pharma4d
As Eli Lilly outperforms Novo in market, it also replaces its rival in annual IDEA Innovation rankings
As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...
Pharma giant Eli Lilly eyes Houston for $5.9B biomanufacturing plant that could bring over 2,000 jobs
Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...
McCord Development site in running for $5.9B Eli Lilly project
Pharma giant Eli Lilly is planning a $5.9 billion investment for a massive pharmaceutical manufacturing facility in McCord ...
Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat
Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...
Fierce Pharma4d
Amid US investment push, Lilly eyes Houston as potential home for $5.9B API plant
With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...